All News

genes.map_.jpg

Pathogenic Impact of microRNA Cotargeting in Lupus

d EurekAlert!

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice.

Read Article
RheumNow Podcast square

Simon Says “Don’t Do This” (1.27.2022)

d Jack Cush, MD

Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything.

Read Article
overlap,heart

Rheumatic Disease - IBD Overlap

d MedPage Today

Nearly one in 10 patients with inflammatory bowel disease (IBD) also have rheumatologic disorders, meaning that specialists have to talk to each other to develop a treatment plan that works for both conditions, a researcher suggested.

Read Article
AI.think_.brain_.jpg

AI Passes U.S. Medical Licensing Exam

d MedPage Today

Two artificial intelligence (AI) programs -- including ChatGPT -- have passed the U.S. Medical Licensing Examination (USMLE), according to two recent papers.

Read Article
rare

VEXAS may be more common than expected

d Jack Cush, MD

A great study of a recently described rheumatologic/hematologic disorder VEXAS (vacuoles, E1-ubiquitin-activating enzyme, X-linked, autoinflammatory, somatic) syndrome recently appeared in JAMA, describing the frequency and presentations of UBA1 variant. 

Read Article
OA,biomarker

Blood Test Identifies Osteoarthritis Progression

d EurekAlert!

A new blood test that can identify progression of osteoarthritis in the knee is more accurate than current methods, providing an important tool to advance research and speed discovery of new therapies.

Read Article
Simon Says “Don’t Do This” Dr. Jack Cush reviews this week’s journal articles, focuses on studies that should not have been done and responds to viewer questions in Ask Cush Anything. https://t.co/ZisyCRxV6L https://t.co/inYDkKKJO3

Links:

Dr. John Cush RheumNow ( View Tweet)
CDC: Nursing home residents not up to date w/COVID-19 vaccines have 30%–50% higher risk for COVID infx vs those up to date. Betw 2022-23 Those vax had COVID rate of 7.2-15.6/1000pts vs 9.5-18.8/1000 pt in those unvaccinated. https://t.co/Eem2H5AMoN https://t.co/o2ZyPVswZp

Links:

Dr. John Cush RheumNow ( View Tweet)
VEXAS may be more common than expected A great study of a recently described rheumatologic/hematologic disorder VEXAS syndrome recently appeared in JAMA, describing the frequency and presentations of UBA1 variant. https://t.co/OFaeH62eHy https://t.co/7znps74Llv

Links:

Dr. John Cush RheumNow ( View Tweet)
Blood Test Identifies Osteoarthritis Progression A new blood test that can identify progression of osteoarthritis in the knee is more accurate than current methods, providing an important tool to advance research and speed discovery of new therapies. https://t.co/hOAjxJhnJG https://t.co/Ehr5imPNQ4

Links:

Dr. John Cush RheumNow ( View Tweet)
A Shortage of Trust I’ve oft heard the truism that “Trust is in short supply”. This is so true. Those I value most, are the ones I trust the most. My nurse practitioner, my front desk gal, my medical partner, and my best friend... https://t.co/AXIDAJQUta https://t.co/GJwQq04dUC

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us on 3/18 and 3/19 in Dallas, Texas or virtually for RheumNow Live! Who is coming? https://t.co/LLUufQDhHv https://t.co/nKTN5KBtuc

Links:

Dr. John Cush RheumNow ( View Tweet)
Variable Pregnancy Outcomes with Belimumab in SLE An analysis looked at outcomes in pregnant SLE exposed to belimumab reported there are few pregnancies and confounding disease and comorbidity factors to provide clear guidance for such patients. https://t.co/pkyAcE0aNr https://t.co/MB4AGmtSdp

Links:

Dr. John Cush RheumNow ( View Tweet)
702 #SLE pts (age 29 yrs) from India, measured plasma 25-hydroxyvitamin-D(25(OH)D) - median levels were 22.83 (13.8–31.8) ng/ml. Low Vit D(< 20) seen in 41.5%; correlated w/ age/geography, & weak neg correlation w/ weak negative correlation w/ SLEDAI2K https://t.co/EUPqJGKAhI https://t.co/MEIL5yd64n

Links:

Dr. John Cush RheumNow ( View Tweet)
Early Ph IIa study of ATI-450 (Zunsemetinib), an investigational selective MAP kinase–2 (MK2) blocker leds to a sustained antiinflammatory effect; studied in 19 RA pts w/ ACR 20/50/70 of 60%/33%/20% at wk 12. https://t.co/IyjJCgdXG2

Links:

Dr. John Cush RheumNow ( View Tweet)

"Dry Synovitis" exist in juvenile arthritis pts? Study of 12 DS pts, says its different from Poly #JIA; onset 6.1 yrs, w/ polyarthritis, no palpable swelling, progressive LOM/contractures, neg ESR/CRP/RF/CCP, +MRI synovitis w/ osteochondral involvement.https://t.co/tL2G7QKBL4 https://t.co/k4QoAmTGYA

Links:

Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/RaFKTqhQjN https://t.co/hH0NcpOoyx

Links:

Dr. John Cush RheumNow ( View Tweet)
Why not end your patient visit with a recitation pledging your service and commitment: "Your coming to see me to day is very important, to the both of us. I pledge to be of service to you. Together WE can certainly improve your health" https://t.co/9U95LoiDQi https://t.co/dMWunEXjWk

Links:

Dr. John Cush RheumNow ( View Tweet)
Recent NEJM has reviewed arthroplasty-associated infection and PJI, noting this is a rare event; notably these infections are caused by skin microorganisms introduced during arthroplasty surgery or may be seeded post-surgically. https://t.co/DXflkGnsdK https://t.co/GgfeSSl4xJ

Links:

Dr. John Cush RheumNow ( View Tweet)
JAK-pot Study: To Cycle or Switch after JAK inhibitor Failure? Data from 17 international registries suggest that for RA patients failing their first JAKi, it did not matter if they were cycled to another JAKi or switched to a bDMARD. https://t.co/xLZveIoaRG https://t.co/tBpJUgOqaN

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×